Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
Xiang Zhou, Leo Rasche, K. Martin Kortüm, et al.
Haematologica (2022) Vol. 108, Iss. 4, pp. 958-968
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Xiaomin Zhang, Hui Zhang, Huixuan Lan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 88
Development of NK cell-based cancer immunotherapies through receptor engineering
Audrey Page, Nicolas Chuvin, Jenny Valladeau‐Guilemond, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 4, pp. 315-331
Open Access | Times Cited: 61
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 34
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 11
A CAR enhancer increases the activity and persistence of CAR T cells
Taha Rakhshandehroo, Shreya R. Mantri, Seyed Heydar Moravej, et al.
Nature Biotechnology (2024)
Closed Access | Times Cited: 9
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Dawn Swan, Deepu Madduri, Jane S. Hocking
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Treg-derived TGF-β1 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myeloma
Disi Zhang, Dong Zhan, Rui Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Bispezifische Antikörper in der Therapie hämatologischer Neoplasien und solider Tumoren
Xiang Zhou, Johannes M. Waldschmidt, Hermann Einsele
Deleted Journal (2025)
Open Access
Progress of immune senescence in multiple myeloma treatment resistance
Yanan Jia, Lixiang Yan, Chenyang Fan, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Bispecific Antibodies in the Treatment of Multiple Myeloma
Xiang Zhou, Xianghui Xiao, K. Martin Kortuem, et al.
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 2, pp. 361-381
Closed Access | Times Cited: 4
Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Federico Riccardi, Carmela Tangredi, Michele Dal Bo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs
Xixi Wan, Yu Tian, Tao Yu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies
P. Joy Ho, Eric Wenlong Li
Internal Medicine Journal (2025)
Open Access
An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy
Georgia Stewart, Simon Tazzyman, Yidan Sun, et al.
Leukemia (2025)
Open Access
Soluble B‐cell maturation antigen in multiple myeloma
Bruno Almeida Costa, Ricardo J. Ortiz, Alexander M. Lesokhin, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 727-738
Closed Access | Times Cited: 2
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Bingjie Fu, Rui Liu, Gongzhizi Gao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?
Xiang Zhou, K. Martin Kortuem, Leo Rasche, et al.
La Presse Médicale (2024), pp. 104265-104265
Open Access | Times Cited: 2
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents
Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 3931-3937
Open Access | Times Cited: 6
Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study
Xiang Zhou, V. Wagner, Lukas Scheller, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 999-1010
Open Access | Times Cited: 1
Single-cell genomics-based immune and disease monitoring in blood malignancies
Anja C. Rathgeber, Leif S. Ludwig, Livius Penter
Clinical Hematology International (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 1
Traversing the bench to bedside journey for iNKT cell therapies
Julie O’Neal, Melissa Mavers, Reyka G. Jayasinghe, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells
Kamonlapat Supimon, Thanich Sangsuwannukul, Piriya Luangwattananun, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113480-113480
Open Access | Times Cited: 1
Update on bi-specific monoclonal antibodies for blood cancers
Geoffrey Shouse
Current Opinion in Oncology (2023) Vol. 35, Iss. 5, pp. 441-445
Closed Access | Times Cited: 3
HDAC inhibition induces CD26 expression on myeloma cells via the c-Myc/Sp1-mediated promoter activation
Hiroko Nishida, R Suzuki, Kiyora Nakajima, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 2, pp. 349-364
Open Access
Structural basis for the recognition of GPRC5D by Talquetamab, a bispecific antibody for Multiple Myeloma
J. Jeong, Junhyeon Park, Geun Young Mo, et al.
Journal of Molecular Biology (2024) Vol. 436, Iss. 20, pp. 168748-168748
Closed Access
Page 1 - Next Page

Scroll to top